



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room - WO66-G609
Silver Spring, MD 20993-0002

Globus Medical, Inc
% Kelly J. Baker, PhD
Vice President, Regulatory and Clinical Affairs
2560 General Armistead Avenue
Audubon, Pennsylvania 19403

SEP 28 2012

Re: P100003
Secure-C Artificial Cervical Disc
Filed: September 17, 2010
Amended: November 10, 2010; July 19, July 28, August 30, October 26, December 19,
2011; January 4, June 20, July 24, August 23, 2012. SEP 28
Procode: MJO

Dear Dr. Baker:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) for the Secure-C Artificial Cervical Disc. This device is indicated in skeletally mature patients for reconstruction of the disc at one level from C3-C7 following single-level discectomy for intractable radiculopathy (arm pain and/or a neurological deficit) with or without neck pain, or myelopathy due to a single-level abnormality localized to the disc space and at least one of the following conditions confirmed by radiographic imaging (CT, MRI, X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height as compared to adjacent levels. The SECURE[®]-C Cervical Artificial Disc is implanted using an anterior approach. Patients should have failed at least 6 weeks of conservative treatment prior to implantation of the SECURE[®]-C Cervical Artificial Disc. We are pleased to inform you that the PMA is approved. You may begin commercial distribution of the device in accordance with the conditions of approval described below.

The sale and distribution of this device are restricted to prescription use in accordance with 21 CFR 801.109 and under section 515(d)(1)(B)(ii) of the Federal Food, Drug, and Cosmetic Act (the act). The device is further restricted under section 515(d)(1)(B)(ii) of the act insofar as the labeling must specify the specific training or experience practitioners need in order to use the device. FDA has determined that these restrictions on sale and distribution are necessary to provide reasonable assurance of the safety and effectiveness of the device. Your device is therefore a restricted device subject to the requirements in sections 502(q) and (r) of the act, in addition to the many other FDA requirements governing the manufacture, distribution, and marketing of devices.

Expiration dating for this device has been established and approved at five years. This is to advise you that the protocol you used to establish this expiration dating is considered an approved protocol for the purpose of extending the expiration dating as provided by 21 CFR 814.39(a)(7).

Continued approval of this PMA is contingent upon the submission of periodic reports, required under 21 CFR 814.84, at intervals of one year (unless otherwise specified) from the date of approval of the original PMA. Two copies of this report, identified as "Annual Report" (please use this title even if the specified interval is more frequent than one year) and bearing the applicable PMA reference number, should be submitted to the address below. The Annual Report should indicate the beginning and ending date of the period covered by the report and should include the information required by 21 CFR 814.84.

In addition to the above, and in order to provide continued reasonable assurance of the safety and effectiveness of the device, the Annual Report must include, separately for each model number (if applicable), the number of devices sold and distributed during the reporting period, including those distributed to distributors. The distribution data will serve as a denominator and provide necessary context for FDA to ascertain the frequency and prevalence of adverse events, as FDA evaluates the continued safety and effectiveness of the device.

You have agreed to provide the following data as part of the annual report:

You must attempt to retrieve all explanted SECURE-C devices (including but not limited to those retrieved from patients in the PAS and ESS) for analysis. All retrievals will be analyzed and reported per the agreed Explant Analysis protocol.

In addition to the Annual Report requirements, you must provide the following data in post-approval study reports (PAS).

1. *Extended Follow-up of Premarket Cohort:* You must perform a 7-year post-approval study (PAS) to evaluate the longer term safety and effectiveness of the SECURE-C Cervical Artificial Disc as compared to ACDF by following the 334 subjects from the pivotal investigational device exemption (IDE) study (220 SECURE-C subjects, and 114 ACDF subjects) annually through 7 years. At each annual (± 4 month) visit, you will collect the following data: Neck Disability Index, neck and right/left arm pain Visual Analog Scale (VAS), health status survey (SF-36), patient satisfaction, neurological status, radiographic information, medication usage and postoperative treatment for pain management, work status, and all adverse events regardless of cause. Radiographic information collected will include: range of motion on flexion/extension films (angulation and translation as well as the correlation of range of motion with outcomes), disc height, radiolucency, device displacement or migration, spinal fusion (control arm only), and heterotopic ossification (including grade, stability over time, and correlation with patient characteristics and postoperative outcomes). You will also collect data on adjacent level degeneration/disease including both surgical and non-surgical adjacent level treatments as well as adjacent level diagnoses and adjacent level range of motion.

The primary objective of the study is to evaluate the overall success rate, using Overall Success Definition 1, defined as:

- Pain/Disability Improvement of at least 25% in the Neck Disability Index (NDI) at 5 years and 7 years compared with the score at baseline;
- No device failures (at the index level) requiring revision, re-operation, removal or supplemental fixation;
- Absence of major complications defined as major vessel injury, neurological damage, or nerve injury; and
- For control fusion patients only, radiographic fusion, as defined by the presence of bridging trabecular bone, without evidence of pseudarthrosis.

You also have agreed to conduct an additional analysis evaluating Overall Success Definition 2, defined as follows:

- Pain/Disability Improvement of at least 15 points in the Neck Disability Index (NDI) at 5 years and 7 years compared with the score at baseline;
- No secondary surgery at the index level, including revision, removal, reoperation and supplemental fixation;
- No potentially device-related adverse events;
- Maintenance or improvement in all components of neurologic status;
- No SECURE-C intraoperative changes in treatment;

Success rates between the randomized investigational and control groups will be compared and assessed for non-inferiority based on a ten percent non-inferiority margin for both overall success analyses. Patients who were non-recoverable non-responders prior to 24 months will carry forward as failures for each subsequent annual visit. Several sensitivity analyses will also be done.

FDA will expect at least 85% follow-up at the 7-year time point to provide sufficient data to evaluate safety and effectiveness.

2. *Enhanced Surveillance System:* You must perform a 10-year Enhanced Surveillance Study (ESS) of the SECURE[®]-C Cervical Artificial Disc to fully characterize adverse events when the device is used in the intended patient population under general conditions of use in the United States and in the rest of the world. You will collect, analyze, and submit all adverse event data including subsequent surgeries, heterotopic ossification, and other device issues. Information will be actively collected from annual surgeon surveys and on the company

website. Information will also be collected passively through complaints and MDRs, explant analysis, and literature review.

In addition, you will actively collect surgeon feedback annually to elicit information related to heterotopic ossification, device malfunction, device removal, or other serious device-related complications. This information will be collected using surgeon surveys. All of the surgeons who have been trained on the use of SECURE®-C in the U.S. will be surveyed annually and the number of surveys issued and received will be reported. If a survey response includes any information related to an adverse event, you will collect additional data as specifically outlined in the ESS protocol and report that data to FDA.

Please be advised that the results from these studies should be included in the labeling as these data become available. Any updated labeling must be submitted to FDA in the form of a PMA Supplement.

Within 30 days of your receipt of this letter, you must submit PMA supplements that include complete protocol for each of your post-approval studies. Your PMA supplements should be clearly labeled as a "Post-Approval Study Protocol" and submitted in triplicate to the address below. Please reference the PMA number above to facilitate processing.

FDA would like to remind you that you are required to submit separate PAS Progress Reports for each of the Post-approval studies listed above, every six months during early stages of the study implementation up to two years and annually thereafter. The reports should clearly be identified as Post-Approval Study Report. Two copies for each study, identified as "PMA Post-Approval Study Report" and bearing the applicable PMA reference number, should be submitted to the address below. For more information on post-approval studies, see the FDA guidance document entitled, "Procedures for Handling Post-Approval Studies Imposed by PMA Order" (www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070974.htm#2).

Be advised that the failure to conduct any such study in compliance with the good clinical laboratory practices in 21 CFR part 58 (if a non-clinical study subject to part 58) or the institutional review board regulations in 21 CFR part 56 and the informed consent regulations in 21 CFR part 50 (if a clinical study involving human subjects) may be grounds for FDA withdrawal of approval of the PMA.

Before making any change affecting the safety or effectiveness of the device, you must submit a PMA supplement or an alternate submission (30-day notice) in accordance with 21 CFR 814.39. All PMA supplements and alternate submissions (30-day notice) must comply with the applicable requirements in 21 CFR 814.39. For more information, please refer to the FDA guidance document entitled, "Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process" (www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089274.htm).

You are reminded that many FDA requirements govern the manufacture, distribution, and marketing of devices. For example, in accordance with the Medical Device Reporting (MDR) regulation, 21 CFR 803.50 and 21 CFR 803.52, you are required to report adverse events for this device. Manufacturers of medical devices, including in vitro diagnostic devices, are required to report to FDA no later than 30 calendar days after the day they receive or otherwise becomes aware of information, from any source, that reasonably suggests that one of their marketed devices:

1. May have caused or contributed to a death or serious injury; or
2. Has malfunctioned and such device or similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

Additional information on MDR, including how, when, and where to report, is available at www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

In accordance with the recall requirements specified in 21 CFR 806.10, you are required to submit a written report to FDA of any correction or removal of this device initiated by you to: (1) reduce a risk to health posed by the device; or (2) remedy a violation of the act caused by the device which may present a risk to health, with certain exceptions specified in 21 CFR 806.10(a)(2). Additional information on recalls is available at www.fda.gov/Safety/Recalls/IndustryGuidance/default.htm.

CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. CDRH will notify the public of its decision to approve your PMA by making available, among other information, a summary of the safety and effectiveness data upon which the approval is based. The information can be found on the FDA CDRH Internet HomePage located at www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/default.htm. Written requests for this information can also be made to the Food and Drug Administration, Dockets Management Branch, (HFA-305), 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The written request should include the PMA number or docket number. Within 30 days from the date that this information is placed on the Internet, any interested person may seek review of this decision by submitting a petition for review under section 515(g) of the act and requesting either a hearing or review by an independent advisory committee. FDA may, for good cause, extend this 30-day filing period.

Failure to comply with any post-approval requirement constitutes a ground for withdrawal of approval of a PMA. The introduction or delivery for introduction into interstate commerce of a device that is not in compliance with its conditions of approval is a violation of law.

You are reminded that, as soon as possible and before commercial distribution of your device, you must submit an amendment to this PMA submission with copies of all approved labeling in final printed form. Final printed labeling that is identical to the labeling approved in draft form will not routinely be reviewed by FDA staff when accompanied by a cover letter stating that the final printed labeling is identical to the labeling approved in draft form. If the final printed labeling is

not identical, any changes from the final draft labeling should be highlighted and explained in the amendment.


All required documents should be submitted in triplicate, unless otherwise specified, to the address below and should reference the above PMA number to facilitate processing. One of those three copies may be an electronic copy (eCopy), in an electronic format that FDA can process, review and archive (general information:

<http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/Pre-marketSubmissions/ucm134508.htm>; clinical and statistical data:
<http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/Pre-marketSubmissions/ucm136377.htm>)

U.S. Food and Drug Administration
Center for Devices and Radiological Health
PMA Document Mail Center – WO66-G609
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

If you have any questions concerning this approval order, please contact Sarah Leismer at 301-796-5650.

Sincerely yours,



Mark N. Melkerson
Director
Division of Surgical, Orthopedic
and Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health